Compare · NSRX vs NVO
NSRX vs NVO
Side-by-side comparison of Nasus Pharma Ltd. (NSRX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NSRX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 5910.3x NSRX ($36.5M).
- Over the past year, NSRX is down 61.7% and NVO is down 29.3% - NVO leads by 32.4 points.
- NVO has hit the wire 4 times in the past 4 weeks while NSRX has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for NSRX).
- Company
- Nasus Pharma Ltd.
- Novo Nordisk A/S
- Price
- $3.07-0.32%
- $48.78+1.22%
- Market cap
- $36.5M
- $215.95B
- 1M return
- -4.36%
- +2.89%
- 1Y return
- -61.72%
- -29.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2025
- News (4w)
- 0
- 4
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NSRX
- Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
- Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
- Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum
- Chief Executive Officer Teleman Dan Benjamin bought $20,305 worth of Ordinary Shares (6,550 units at $3.10), increasing direct ownership by 4% to 163,541 units (SEC Form 4)
- SEC Form 6-K filed by Nasus Pharma Ltd.
- Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
- Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
- SEC Form S-8 filed by Nasus Pharma Ltd.
- SEC Form SCHEDULE 13G filed by Nasus Pharma Ltd.
- Nasus Pharma to Participate in Upcoming Investor Conferences
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S